Ascendis Pharma A/S - ADR logo

ASND

Ascendis Pharma A/S - ADR

$95.61

Earnings Summary

Revenue
$6.83Mn
Net Profits
$-125.5Mn
Net Profit Margins
-1837.99%

Highlights

Revenue:

Ascendis Pharma A/S - ADR’s revenue jumped 815.28% since last year same period to $6.83Mn in the Q1 2022. On a quarterly growth basis, Ascendis Pharma A/S - ADR has generated 39.4% jump in its revenue since last 3-months.

Net Profits:

Ascendis Pharma A/S - ADR’s net profit fell -99.86% since last year same period to $-125.5Mn in the Q1 2022. On a quarterly growth basis, Ascendis Pharma A/S - ADR has generated -18.32% fall in its net profits since last 3-months.

Net Profit Margins:

Ascendis Pharma A/S - ADR’s net profit margin jumped 78.16% since last year same period to -1837.99% in the Q1 2022. On a quarterly growth basis, Ascendis Pharma A/S - ADR has generated 15.12% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ascendis Pharma A/S - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-2.18
EPS Estimate Current Year
-2.18

Highlights

EPS Estimate Current Quarter:

Ascendis Pharma A/S - ADR’s earning per share (EPS) estimates for the current quarter stand at -2.18 - a -9% fall from last quarter’s estimates.

EPS Estimate Current Year:

Ascendis Pharma A/S - ADR’s earning per share (EPS) estimates for the current year stand at -2.18.

Key Ratios

Key ratios of the Ascendis Pharma A/S - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-2.21
Return on Assets (ROA)
-0.28
Return on Equity (ROE)
-0.61
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Ascendis Pharma A/S - ADR’s earning per share (EPS) fell -88.89% since last year same period to -2.21 in the Q1 2022. This indicates that the Ascendis Pharma A/S - ADR has generated -88.89% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S - ADR’s return on assets (ROA) stands at -0.28.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S - ADR’s return on equity (ROE) stands at -0.61.

Dividend Per Share (DPS):

Ascendis Pharma A/S - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-2
-2.21
-10.5%

Company Information

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Organisation
Ascendis Pharma A/S - ADR
Headquarters
Tuborg Boulevard 5, Hellerup, Denmark
Employees
2.02K
Industry
Health Technology
CEO
Jan Moeller Mikkelsen